fenofibrate has been researched along with Hyperprolactinaemia in 1 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| " Because of concomitant atherogenic dyslipidemia, all patients were treated with fenofibrate (200 mg daily) for 12 weeks." | 7.91 | Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia. ( Krysiak, R; Okopień, B; Szkróbka, W, 2019) |
| " Because of concomitant atherogenic dyslipidemia, all patients were treated with fenofibrate (200 mg daily) for 12 weeks." | 3.91 | Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia. ( Krysiak, R; Okopień, B; Szkróbka, W, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Krysiak, R | 1 |
| Szkróbka, W | 1 |
| Okopień, B | 1 |
1 other study available for fenofibrate and Hyperprolactinaemia
| Article | Year |
|---|---|
Different effects of fenofibrate on cardiometabolic risk factors in young women with and without hyperprolactinemia.
Topics: Adult; Age Factors; Biomarkers; Bromocriptine; Cardiovascular Diseases; Case-Control Studies; Dopami | 2019 |